文献速递脊柱关节炎

接受乌帕替尼治疗的银屑病关节炎或中轴型脊柱关节炎患者中骨骼外表现的发展情况

Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.
PubMed 文献 · Arthritis Rheumatol · 2025-01-24

该分析基于五项临床试验数据,评估银屑病关节炎(PsA)或中轴型脊柱关节炎(axSpA)患者接受乌帕替尼15 mg后骨骼外表现(EMM)的发生情况。结果显示EMM总体发生率较低,乌帕替尼15 mg组葡萄膜炎发生率在放射学axSpA中数值上低于安慰剂组(2.8 vs 7.5事件/100患者年),且无论治疗如何,有葡萄膜炎病史者似乎更易发生未来葡萄膜炎事件。

要点

  • 在PsA中,无论治疗或既往EMM史,葡萄膜炎和IBD发生率均低,乌帕替尼15 mg与阿达木单抗发生率相似。
  • 在放射学axSpA中,乌帕替尼15 mg组葡萄膜炎发生率数值上低于安慰剂组(2.8 vs 7.5事件/100患者年)。
  • 在放射学axSpA中,有葡萄膜炎病史者未来葡萄膜炎事件发生率数值上高于无病史者。

核心结论

  • 在脊柱关节炎患者中,乌帕替尼15 mg治疗时EMM的总体发生率较低。
  • 乌帕替尼15 mg组葡萄膜炎发生率数值上低于安慰剂组,尤其是在放射学axSpA中。
  • 在放射学axSpA中,无论接受何种治疗,有葡萄膜炎病史似乎使患者易发生未来葡萄膜炎事件。

研究设计与样本

  • 分析五项临床试验数据(截至2022年8月15日),包括PsA(2项)、放射学axSpA(2项)和 nr-axSpA(1项)。
  • 评估接受安慰剂、乌帕替尼15 mg或阿达木单抗(仅PsA)治疗的患者中EMM(包括葡萄膜炎、IBD和银屑病)的治疗中出现的不良事件,以暴露调整事件率(每100患者年事件数[E/100 PY])报告。

主要发现

  • 大多数患者(87.1%-99.3%)基线时无EMM病史。
  • 在PsA中,无论治疗或既往EMM史,葡萄膜炎和IBD发生率均低,乌帕替尼15 mg与阿达木单抗发生率相似。
  • 在放射学axSpA中,乌帕替尼15 mg组葡萄膜炎发生率为2.8 E/100 PY,安慰剂组为7.5 E/100 PY;无葡萄膜炎病史者中乌帕替尼15 mg组为0.6 E/100 PY、安慰剂组为1.2 E/100 PY,有葡萄膜炎病史者中乌帕替尼15 mg组为2.1 E/100 PY、安慰剂组为6.2 E/100 PY;无论治疗或病史如何,IBD和银屑病发生率均低。
  • 在nr-axSpA中,无论病史如何葡萄膜炎发生率均低,乌帕替尼15 mg组为0.9 E/100 PY,安慰剂组为2.1 E/100 PY;IBD和银屑病发生率低或缺失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg. METHODS: Data (cutoff: August 15, 2022) from five clinical trials in PsA (2), radiographic axSpA (r-axSpA; previously ankylosing spondylitis) (2), and nonradiographic axSpA (nr-axSpA) (1) were analyzed. Treatment-emergent adverse events of EMMs including uveitis, inflammatory bowel disease (IBD), and psoriasis were assessed in patients treated with placebo, upadacitinib 15 mg, or adalimumab (PsA only) and are reported as exposure-adjusted event rates (events per 100 patient-years [E/100 PY]). RESULTS: Most patients (87.1%-99.3%) did not have a history of EMMs at baseline. In PsA, development of uveitis and IBD were low regardless of treatment or prior EMM history; rates were similar with upadacitinib 15 mg and adalimumab. In r-axSpA, development of uveitis was numerically lower (E/100 PY) in patients treated with upadacitinib 15 mg (2.8) versus placebo (7.5) and in patients with no history of uveitis (upadacitinib 15 mg 0.6; placebo 1.2) versus a history of uveitis (upadacitinib 15 mg 2.1; placebo 6.2); occurrence of IBD and psoriasis were low regardless of treatment or history. In nr-axSpA, development of uveitis was low regardless of history but was numerically lower in patients treated with upadacitinib 15 mg (0.9) versus placebo (2.1); occurrence of IBD and psoriasis were low or absent. CONCLUSION: In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r-axSpA. Regardless of treatment in r-axSpA, having a history of uveitis appeared to predispose patients for future uveitis events.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Poddubnyy D, Parikh B, Elewaut D, et al. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025. PMID: 39624020. doi:10.1002/art.43069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。